Thus, our results where increased serum TGF‐β1 at 3 months of treatment predicts 6‐months MRD status suggest that targeting and/or using TGF‐β1 to monitor MCL patients is an interesting prognostic tool. Here, TGFB1 is linked to mantle cell lymphoma.